Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC023 ONC206 in pediatric and young adult diffuse midline glioma and recurrent malignant CNS tumors
NL-OMON59703Phase 1Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Mar 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONC206 in diffuse midline glioma (DMG) and Neuro-Oncological Malignancies (4 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose and Tumor penetration / target validation. Started Mar 2026; status: recruiting.
02
Drugs
ONC206
03
Conditions
diffuse midline glioma (DMG)Neuro-Oncological Malignancies
Beyond the preview
Go deeper on NL-OMON59703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59703.